Patent ID: 11963521
Assignee: REGENERON PHARMACEUTICALS, INC.
Field: Biotechnology (Chemistry)
Classification: CPC A  C | IPC A  C  G

Claim 0:
1. A targeting vector for humanizing an endogenous IL-4Rα gene in a rodent, comprising
a nucleic acid sequence of a human IL-4Rα gene, flanked by nucleic acid sequences that are homologous to nucleic acid sequences at a rodent IL-4Rα locus and mediate integration of the nucleic acid sequence of the human IL-4Rα gene into the rodent IL-4Rα locus,
wherein the nucleic acid sequence of the human IL-4Rα gene comprises the ATG initiation codon of exon 1 through exon 5 of the human IL-4Rα gene,
wherein integration of the nucleic acid sequence of the human IL-4Rα gene into the rodent IL-4Ra locus results in a replacement of a genomic fragment of the rodent IL-4Rα gene to form a humanized IL-4Rα gene,
wherein the genomic fragment of the rodent IL-4Rα gene being replaced comprises the ATG initiation codon of exon 1 through exon 5 of the rodent IL-4Rα gene,
wherein the humanized IL-4Rα gene (i) encodes a humanized IL-4Rα protein comprising the transmembrane domain and the cytoplasmic domain of the rodent IL-4Rα protein encoded by the rodent IL-4Rα gene, or (ii) comprises the ATG initiation codon of exon 1 through exon 5 of the human IL-4Rα gene, and exons 6-9 of the rodent IL-4Rα gene,
wherein expression of the humanized IL-4Rα gene is under control of rodent IL-4Rα regulatory elements at the endogenous rodent IL-4Rα locus, and
wherein the rodent is a mouse.